Maxcyte (MXCT) news
Recent news
Liontrust investment partners reports 5.0% stake in MaxCyte as of Oct. 14 - SEC filing
AInvest Wire · 8h agoMaxCyte: Outlook FY revenue expected to be approximately $34 million
AInvest Wire · 1d agoMaxCyte Q3 revenue USD 8.1 million vs. IBES estimate USD 7.05 million
MaxCyte, Inc. reported third-quarter revenue of $8.1 million for the period ending September 30, 2025, exceeding the IBES consensus estimate . The results reflect the company’s ongoing efforts to expand its presence in the biotechnology and cell therapy markets. While the firm did not provide a…
AInvest Wire · 1d agoMaxCyte raises FY 2026 rev guidance
AInvest Wire · 1d agoMaxCyte appoints Sidharth Kapileshwar as chief corporate development officer
MaxCyte, Inc. has announced the appointment of Sidharth Kapileshwar as chief corporate development officer , effective immediately. In this role, Kapileshwar will oversee strategic initiatives related to corporate development, including mergers and acquisitions, partnerships, and business…
AInvest Wire · Sep 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.